What is NexImmune Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. NexImmune's interest expense for the
three
months ended in Jun. 2024 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. NexImmune's Operating Income for the
three
months ended in Jun. 2024 was $ -2.73 Mil. NexImmune's Interest Expense for the
three
months ended in Jun. 2024 was $ 0.00 Mil.
NexImmune has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NexImmune Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NexImmune (OTCPK:NEXI) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
NexImmune's Interest Expense for the
three
months ended in Jun. 2024 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Jun. 2024 was $-2.73 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Jun. 2024 was $0.00 Mil.
NexImmune's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as
| NexImmune had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. NexImmune Inc has enough cash to cover all of its debt. Its financial situation is stable.
NexImmune Business Description
Traded in Other Exchanges
N/A
Address
9119 Gaither Road, Gaithersburg, MD, USA, 20877
NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
Executives
| Alan S. Roemer |
director |
C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018 |
| Timothy Stover |
officer: VP, Corporate Controller |
C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
| Sol J Barer |
director |
C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116 |
| Zhengbin Yao |
director |
10301 STELLA LINK ROAD, HOUSTON TX 77025 |
| Leena Gandhi |
director |
C/O NEXIMMUNE, 9119 GAITHER ROAD, GAITHERSBURG MD 20878 |
| Timothy Bertram |
director |
C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403 |
| Paul D'angio |
director |
C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
| Grant Verstandig |
director |
C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
| Mathias Oelke |
officer: Chief Science Officer |
C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20878 |
| Kristi Jones |
officer: Chief Operating Officer |
C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
| Jerome B Zeldis |
officer: EVP of R&D |
8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258 |
| Scott Carmer |
director, officer: President and CEO |
C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
| John Trainer |
officer: Chief Financial Officer |
C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
| Robert Douglas Knight |
officer: Chief Medical Officer |
C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NEXI has been successfully added to your 